Cleave Therapeutics, Inc.
VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases
3 employees · est. 2011 · San Francisco, United States
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (M
221 employees · est. 2018 · Boston, United States
Cleave Therapeutics, Inc. is the older company (2011 vs 2018); Monte Rosa Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Cleave Therapeutics, Inc. | Monte Rosa Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2011 older | 2018 |
| Headquarters | ||
| Headquarters | San Francisco, United States | Boston, United States |
| Employees | ||
| Employees | 3 | 221 larger |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series C | IPO |
| Total Funding | ||
| Total Funding | $91.95M | $570.50M |
| Funding Rounds | ||
| Funding Rounds | 5 | 9 |
| Services | ||
| Services | Not tracked yet | Discovery and development of molecular glue degraders (MGDs), Research on protein degradation for medical therapeutics, Innovation in AI and structural biology for drug discovery |
| Target Customers | ||
| Target Customers | Not tracked yet | Pharmaceutical companies, Healthcare providers, Medical researchers, Investors in biotechnology |
| Taxonomy | ||
| Taxonomy | VCP/p97 Inhibitors, Oncology, Neurodegenerative Diseases, Biopharmaceutical, Protein Homeostasis, Cellular Stress Pathways, Cancer Stress Pathways, Drug Discovery, Drug Development, AML (Acute Myeloid Leukemia), Mitochondrial Health, Protein-Degradation Pathways, Small-Molecule Drugs, Selective Inhibitors, Therapeutic Innovation | Clinical-stage, Molecular Glue Degraders, Oncology, Autoimmune Diseases, Inflammatory Diseases, QuEEN Discovery Engine, AI-guided Chemistry, Chemical Libraries, Structural Biology, Proteomics, Protein Degradation, Therapeutic Development, Selective Drug Design, Targeted Therapy |
| Website | ||
| Website | cleavetherapeutics.com | monterosatx.com |
About Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc., founded in 2011, is a pioneering biopharmaceutical company headquartered in the United States. It focuses on developing VCP/p97 inhibitors for applications in oncology and neurodegenerative diseases. The company positions itself as a leader in targeting the valosin-contain...
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, founded in 2018, is a United States-based clinical-stage biotechnology company at the forefront of developing highly selective molecular glue degrader (MGD) medicines. These innovations target patients with serious conditions across oncology, autoimmune, and inflammatory dis...
We will tell you when either one moves
BounceWatch watches Cleave Therapeutics, Inc. and Monte Rosa Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Cleave Therapeutics, I... and Monte Rosa Therapeutic... — by email.
Frequently Asked Questions
Compare Cleave Therapeutics, Inc. with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Cleave Therapeutics, Inc. on 11 Mar 2026, and Monte Rosa Therapeutics on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
